Literature DB >> 23059871

Will T-cell therapy for cancer ever be a standard of care?

M K Brenner1.   

Abstract

Cellular therapies for cancer are showing increasing efficacy but their introduction as a 'standard of care' for these disorders is hampered by technical, regulatory and financial concerns. This review identifies some of the major problems and suggests potential solutions.

Entities:  

Mesh：

Year:  2012        PMID： 23059871     DOI： 10.1038/cgt.2012.74

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


  8 in total

1.  Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.

Authors:  Mark E Dudley; Colin A Gross; Robert P T Somerville; Young Hong; Nicholas P Schaub; Shannon F Rosati; Donald E White; Debbie Nathan; Nicholas P Restifo; Seth M Steinberg; John R Wunderlich; Udai S Kammula; Richard M Sherry; James C Yang; Giao Q Phan; Marybeth S Hughes; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

Review 2.  Past, present and future targets for immunotherapy in ovarian cancer.

Authors:  Carlton L Schwab; Diana P English; Dana M Roque; Monica Pasternak; Alessandro D Santin
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

Review 3.  Immunotherapeutic strategies to target prognostic and predictive markers of cancer.

Authors:  Michael S Magee; Adam E Snook; Glen P Marszalowicz; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

4.  Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

Authors:  Sid P Kerkar; Anthony J Leonardi; Nicolas van Panhuys; Ling Zhang; Zhiya Yu; Joseph G Crompton; Jenny H Pan; Douglas C Palmer; Richard A Morgan; Steven A Rosenberg; Nicholas P Restifo
Journal:  Mol Ther       Date:  2013-04-09       Impact factor: 11.454

Review 5.  Towards a commercial process for the manufacture of genetically modified T cells for therapy.

Authors:  A D Kaiser; M Assenmacher; B Schröder; M Meyer; R Orentas; U Bethke; B Dropulic
Journal:  Cancer Gene Ther       Date:  2015-01-23       Impact factor: 5.987

6.  An efficient low cost method for gene transfer to T lymphocytes.

Authors:  Leonardo Chicaybam; Andressa Laino Sodre; Bianca Azevedo Curzio; Martin Hernan Bonamino
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

Review 7.  Gene therapy on the move.

Authors:  Kerstin B Kaufmann; Hildegard Büning; Anne Galy; Axel Schambach; Manuel Grez
Journal:  EMBO Mol Med       Date:  2013-09-17       Impact factor: 12.137

Review 8.  Are clinical trials with mesenchymal stem/progenitor cells too far ahead of the science? Lessons from experimental hematology.

Authors:  Darwin J Prockop; Susan E Prockop; Ivan Bertoncello
Journal:  Stem Cells       Date:  2014-12       Impact factor: 6.277
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.